Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B03XA02

Aranesp(darbepoetin alfa)

Anemia;Cancer;Kidney Failure, Chronic

Marketing Authorisation Holder: Amgen Europe B.V.

EMA Authorisation: 08/06/2001

INN: darbepoetin alfa

Indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Aranesp — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.